Literature DB >> 20209629

mu-Opioid receptor knockout mice are insensitive to methamphetamine-induced behavioral sensitization.

Xine Shen1, Chris Purser, Lu-Tai Tien, Chi-Tso Chiu, Ian A Paul, Rodney Baker, Horace H Loh, Ing K Ho, Tangeng Ma.   

Abstract

Repeated administration of psychostimulants to rodents can lead to behavioral sensitization. Previous studies, using nonspecific opioid receptor (OR) antagonists, revealed that ORs were involved in modulation of behavioral sensitization to methamphetamine (METH). However, the contribution of OR subtypes remains unclear. In the present study, using mu-OR knockout mice, we examined the role of mu-OR in the development of METH sensitization. Mice received daily intraperitoneal injection of drug or saline for 7 consecutive days to initiate sensitization. To express sensitization, animals received one injection of drug (the same as for initiation) or saline on day 11. Animal locomotor activity and stereotypy were monitored during the periods of initiation and expression of sensitization. Also, the concentrations of METH and its active metabolite amphetamine in the blood were measured after single and repeated administrations of METH. METH promoted significant locomotor hyperactivity at low doses and stereotyped behaviors at relative high doses (2.5 mg/kg and above). Repeated administration of METH led to the initiation and expression of behavioral sensitization in wild-type mice. METH-induced behavioral responses were attenuated in the mu-OR knockout mice. Haloperidol (a dopamine receptor antagonist) showed a more potent effect in counteracting METH-induced stereotypy in the mu-OR knockout mice. Saline did not induce behavioral sensitization in either genotype. No significant difference was observed in disposition of METH and amphetamine between the two genotypes. Our study indicated that the mu-opioid system is involved in modulating the development of behavioral sensitization to METH. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20209629      PMCID: PMC3086557          DOI: 10.1002/jnr.22386

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  28 in total

1.  Proceedings: Amphetamine and apomorphine responses in the rat after lesion of mesolimbic or striatal dopamine neurones.

Authors:  S D Iversen; P H Kelly; R J Miller; P Seviour
Journal:  Br J Pharmacol       Date:  1975-06       Impact factor: 8.739

2.  Fenfluramine-induced increase in preproenkephalin mRNA levels in the striatum: interaction between the serotonergic, glutamatergic, and dopaminergic systems.

Authors:  I Liste; A Muñoz; M J Guerra; J L Labandeira-Garcia
Journal:  Synapse       Date:  2000-03-01       Impact factor: 2.562

3.  Opioids excite dopamine neurons by hyperpolarization of local interneurons.

Authors:  S W Johnson; R A North
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

Review 4.  Review. The incentive sensitization theory of addiction: some current issues.

Authors:  Terry E Robinson; Kent C Berridge
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-10-12       Impact factor: 6.237

5.  Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine.

Authors:  C W Callaway; R Kuczenski; D S Segal
Journal:  Brain Res       Date:  1989-12-25       Impact factor: 3.252

6.  D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine.

Authors:  H Ujike; K Akiyama; S Otsuki
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine.

Authors:  R T Matthews; D C German
Journal:  Neuroscience       Date:  1984-03       Impact factor: 3.590

8.  Dual ultrastructural localization of enkephalin and tyrosine hydroxylase immunoreactivity in the rat ventral tegmental area: multiple substrates for opiate-dopamine interactions.

Authors:  S R Sesack; V M Pickel
Journal:  J Neurosci       Date:  1992-04       Impact factor: 6.167

9.  Induction of oral stereotypy following amphetamine microinjection into a discrete subregion of the striatum.

Authors:  A E Kelley; C G Lang; A M Gauthier
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

View more
  18 in total

1.  Methamphetamine-induced expression of zif268 mRNA is prevented by haloperidol in mice lacking mu-opioid receptor.

Authors:  Lu-Tai Tien; Ing-Kang Ho; Tangeng Ma
Journal:  Neurotoxicology       Date:  2010-02-23       Impact factor: 4.294

Review 2.  Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.

Authors:  Kelly E Courtney; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

Review 3.  The sigma-1 receptor as a regulator of dopamine neurotransmission: A potential therapeutic target for methamphetamine addiction.

Authors:  Danielle O Sambo; Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Pharmacol Ther       Date:  2018-01-31       Impact factor: 12.310

4.  Opioid sensitivity in mice selectively bred to consume or not consume methamphetamine.

Authors:  Emily C Eastwood; Tamara J Phillips
Journal:  Addict Biol       Date:  2012-11-12       Impact factor: 4.280

5.  Pseudoginsenoside-F11 inhibits methamphetamine-induced behaviors by regulating dopaminergic and GABAergic neurons in the nucleus accumbens.

Authors:  Kequan Fu; Huiyang Lin; Yoshiaki Miyamoto; Chunfu Wu; Jingyu Yang; Kyosuke Uno; Atsumi Nitta
Journal:  Psychopharmacology (Berl)       Date:  2015-12-01       Impact factor: 4.530

6.  Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.

Authors:  E C Eastwood; T J Phillips
Journal:  Genes Brain Behav       Date:  2013-11-18       Impact factor: 3.449

7.  Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion.

Authors:  Rana A K Singh; Therese A Kosten; Berma M Kinsey; Xiaoyun Shen; Angel Y Lopez; Thomas R Kosten; Frank M Orson
Journal:  Pharmacol Biochem Behav       Date:  2012-08-28       Impact factor: 3.533

8.  Role of MT1 melatonin receptors in methamphetamine-induced locomotor sensitization in C57BL/6 mice.

Authors:  Anthony J Hutchinson; Jason Ma; Jiabei Liu; Randall L Hudson; Margarita L Dubocovich
Journal:  Psychopharmacology (Berl)       Date:  2013-08-11       Impact factor: 4.530

Review 9.  Pharmacotherapy for stimulant-related disorders.

Authors:  Colin N Haile; Thomas R Kosten
Journal:  Curr Psychiatry Rep       Date:  2013-11       Impact factor: 5.285

Review 10.  15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse.

Authors:  Pauline Charbogne; Brigitte L Kieffer; Katia Befort
Journal:  Neuropharmacology       Date:  2013-09-10       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.